Bronchodilator effect of sodium cromoglycate and its clinical implications.
The bronchodilator effect of sodium cromoglycate (SCG) solution was investigated. Twenty asthmatic children aged 6-15 years (mean 11.3) were examined and the action of SCG compared with that of salbutamol and placebo (water). SCG produced a significantly raised peak expiratory flow rate (PEFR) before exercise, which reached a maximum immediately after exercise. The bronchodilatation was sustained for up to four hours, when the PEFR was still significantly above the resting value. This effect was comparable in degree and duration with that of salbutamol. In contrast, placebo produced insignificant bronchodilatation before exercise but significant albeit short-lived bronchodilatation after exercise, which is the characteristic response of the asthmatic to a short period of exercise. This powerful bronchodilator action of SCG and its equally potent inhibitory action on exercise-induced bronchoconstriction was achieved by administering the solution via an efficient nebuliser. In order to achieve maximum clinical effect the SCG must, therefore, be given in this form.
D000293:Adolescent; D000420:Albuterol / Q000494:pharmacology; D001250:Asthma, Exercise-Induced / Q000503:physiopathology / Q000517:prevention & control; D001980:Bronchi / Q000187:drug effects*; D002648:Child; D004205:Cromolyn Sodium / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D010366:Peak Expiratory Flow Rate; D013997:Time Factors
D004205:Cromolyn Sodium; D000420:Albuterol